Forbion, the venture capital group, has appointed Gijs van den Brink as an operating partner with a focus on supporting the Netherlands-based company’s portfolio companies. Dr van den Brink joins Forbion from Roche, where, from 2019, he was a senior vice president and a member of the Pharma Research and Early Development leadership team. He was also senior vice president and global head of immunology discovery, early and late-stage clinical development at GSK Plc. This followed an academic medical career, including as professor of experimental gastroenterology at the University of Amsterdam.
Forbion announced the appointment on 12 December 2024.
Copyright 2025 Evernow Publishing Ltd.